Geoffrey Beran Rose Sells 6,947 Shares of Pulmonx Co. (NASDAQ:LUNG) Stock

Pulmonx Co. (NASDAQ:LUNG - Get Free Report) insider Geoffrey Beran Rose sold 6,947 shares of Pulmonx stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $3.13, for a total value of $21,744.11. Following the completion of the transaction, the insider now owns 386,331 shares in the company, valued at approximately $1,209,216.03. The trade was a 1.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Pulmonx Trading Down 3.1%

Shares of NASDAQ LUNG traded down $0.10 during trading on Wednesday, reaching $3.08. The company had a trading volume of 249,343 shares, compared to its average volume of 312,447. The company's fifty day moving average price is $4.49 and its 200-day moving average price is $6.01. Pulmonx Co. has a 12 month low of $2.83 and a 12 month high of $9.37. The stock has a market cap of $123.99 million, a P/E ratio of -2.14 and a beta of 0.52. The company has a quick ratio of 6.77, a current ratio of 7.70 and a debt-to-equity ratio of 0.40.

Pulmonx (NASDAQ:LUNG - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.01. The firm had revenue of $22.54 million for the quarter, compared to analyst estimates of $22.03 million. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. As a group, research analysts expect that Pulmonx Co. will post -1.55 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Deerfield Management Company L.P. Series C acquired a new position in shares of Pulmonx in the 4th quarter valued at about $10,421,000. Deutsche Bank AG lifted its stake in shares of Pulmonx by 4.2% in the 1st quarter. Deutsche Bank AG now owns 1,147,105 shares of the company's stock valued at $7,720,000 after purchasing an additional 46,116 shares during the period. Geode Capital Management LLC lifted its stake in shares of Pulmonx by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 902,240 shares of the company's stock valued at $6,128,000 after purchasing an additional 9,454 shares during the period. Altium Capital Management LLC lifted its stake in shares of Pulmonx by 63.0% in the 4th quarter. Altium Capital Management LLC now owns 815,000 shares of the company's stock valued at $5,534,000 after purchasing an additional 315,000 shares during the period. Finally, Rock Springs Capital Management LP lifted its stake in shares of Pulmonx by 11.7% in the 4th quarter. Rock Springs Capital Management LP now owns 772,151 shares of the company's stock valued at $5,243,000 after purchasing an additional 80,851 shares during the period. 91.04% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on LUNG shares. Piper Sandler restated an "overweight" rating and set a $9.00 price objective (down previously from $10.00) on shares of Pulmonx in a research report on Thursday, May 1st. Jefferies Financial Group started coverage on Pulmonx in a research report on Monday, March 10th. They set a "buy" rating on the stock. D. Boral Capital restated a "buy" rating and set a $17.00 price objective on shares of Pulmonx in a research report on Thursday, May 1st. Morgan Stanley started coverage on Pulmonx in a research report on Monday, March 10th. They set an "equal weight" rating on the stock. Finally, Canaccord Genuity Group reduced their price objective on Pulmonx from $16.00 to $15.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, Pulmonx presently has a consensus rating of "Moderate Buy" and an average target price of $11.59.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.